Feng Zhang (Xiao Qiang/Imaginechina via AP Images)

Ver­tex goes back to gene-edit­ing part­ner — and sci­ence founder Feng Zhang — to add $1.2B deal on en­gi­neered cell ther­a­pies

Close to 3 years af­ter Ver­tex helped Ar­bor Biotech­nolo­gies get off the ground with a rep­u­ta­tion-build­ing al­liance to build gene-edit­ing tools for a suite of core dis­eases, in­clud­ing cys­tic fi­bro­sis, they’ve come back to go up to $1.2 bil­lion deep­er in­to their shared jour­ney of dis­cov­ery. On­ly this time they’re col­lab­o­rat­ing on ex vi­vo en­gi­neered cell ther­a­pies.

They’ve broad­ened the sphere of their work with the biotech, go­ing af­ter type 1 di­a­betes as well as sick­le cell dis­ease and be­ta tha­lassemia — plus a few that are be­ing left off the radar for now.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.